A week-by-week breakdown of the Retatrutide research timeline — from first-dose appetite suppression through the rapid weight loss phase to maximum effect, based on clinical trial data.
All three receptors (GLP-1, GIP, glucagon) respond within 24–48 hours. The glucagon receptor component activates thermogenesis from day 1 — increasing resting energy expenditure beyond appetite suppression alone. Nausea is more pronounced than semaglutide or tirzepatide at the starting dose.
Most researchers see 2–4 kg of weight loss by week 4 — faster than semaglutide or tirzepatide at comparable timepoints. The glucagon-driven thermogenesis contributes to energy expenditure even before significant caloric restriction occurs.
The standard titration increases dose every 4 weeks. GI side effects are most pronounced during this phase — nausea rates of 47–58% at therapeutic doses. Slow titration (6–8 week steps) significantly reduces side effects. Weight loss of 1–2 kg/week is typical at therapeutic doses.
At 8–12 mg/week (therapeutic range), weight loss averages 1.5–2.5% of body weight per month. Phase 2 subjects lost an average of 17% of body weight by week 24 — the fastest rate of any GLP-class compound studied.
Weight loss continues through week 48 in Phase 2 trials. Maximum weight loss of ~24% is achieved at week 48 — notably faster than tirzepatide's ~22% at 72 weeks. Visceral fat reduction is particularly pronounced with retatrutide.
Weight regain after stopping retatrutide has not been studied in long-term extension trials (Phase 2 only). Based on the GLP-1 class effect and the glucagon component, weight regain is expected to be similar to or greater than tirzepatide. Maintenance dosing is anticipated to be necessary.
Appetite suppression and thermogenesis begin within the first week. Measurable weight loss (2–4 kg) typically occurs within 4 weeks — faster than semaglutide or tirzepatide at comparable timepoints. Maximum weight loss (~24% of body weight) is achieved at approximately 48 weeks in Phase 2 trials.
Phase 2 data suggests retatrutide produces greater weight loss faster than tirzepatide. Retatrutide achieved ~24% weight loss at 48 weeks; tirzepatide achieved ~22% at 72 weeks. The glucagon receptor component drives thermogenesis that accelerates fat loss beyond appetite suppression alone.
Retatrutide has a half-life of approximately 6 days. After stopping, it takes approximately 5–7 half-lives (30–42 days) to clear the system. Appetite typically returns within 2–4 weeks of stopping.
The first week typically involves nausea (most common), reduced appetite, and occasional fatigue. Retatrutide has higher nausea rates than semaglutide or tirzepatide (47–58% at therapeutic doses) due to the glucagon receptor component. Evening dosing and slow titration significantly reduce first-week side effects.
No. Retatrutide completed Phase 2 trials and is currently in Phase 3 trials. It is not FDA approved for any indication. Research-grade retatrutide is available from suppliers like Purgo Labs for research purposes only.
Purgo Labs provides pharmaceutical-grade retatrutide with third-party COAs. Use code HEALTH for 15% off your first order.
Buy Retatrutide at Purgo LabsMedical Disclaimer: All content on this site is for educational and research purposes only. Research peptides are not FDA-approved for human use. Always consult a qualified healthcare professional before considering any peptide or supplement protocol. Nothing on this site constitutes medical advice, diagnosis, or treatment.